Tags

Type your tag names separated by a space and hit enter

Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
Neuropsychiatr Dis Treat. 2020; 16:1459-1472.ND

Abstract

Depression accounts for the predominant burden associated with bipolar disorder. The identification and management of bipolar depression are challenging, since bipolar depression differs from unipolar depression, responding poorly to traditional antidepressants, which may also induce a switch to hypomania/mania, mixed states and/or cause rapid cycling. Current treatment options for bipolar depression are limited and guidelines vary greatly in their recommendations, reflecting gaps and inconsistencies in the current evidence base. Moreover, some treatment options, such as quetiapine and olanzapine-fluoxetine, although clearly efficacious, may be associated with adverse cardiometabolic side effects, which can be detrimental to the long-term physical health and well-being of patients, increasing the likelihood of treatment non-adherence and relapse. Evidence for some more recent therapeutic options, including lurasidone and cariprazine, suggests that patients' symptoms can be effectively managed without compromising their physical health. In addition, novel agents targeting alternative neurotransmitter pathways and inflammatory processes (such as ketamine and N-acetyl cysteine) are emerging as promising potential options for the treatment of bipolar depression in the future.

Authors+Show Affiliations

Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, London, UK.Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, London, UK.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32606699

Citation

Yalin, Nefize, and Allan H. Young. "Pharmacological Treatment of Bipolar Depression: what Are the Current and Emerging Options?" Neuropsychiatric Disease and Treatment, vol. 16, 2020, pp. 1459-1472.
Yalin N, Young AH. Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options? Neuropsychiatr Dis Treat. 2020;16:1459-1472.
Yalin, N., & Young, A. H. (2020). Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options? Neuropsychiatric Disease and Treatment, 16, 1459-1472. https://doi.org/10.2147/NDT.S245166
Yalin N, Young AH. Pharmacological Treatment of Bipolar Depression: what Are the Current and Emerging Options. Neuropsychiatr Dis Treat. 2020;16:1459-1472. PubMed PMID: 32606699.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options? AU - Yalin,Nefize, AU - Young,Allan H, Y1 - 2020/06/09/ PY - 2020/01/08/received PY - 2020/04/15/accepted PY - 2020/7/2/entrez PY - 2020/7/2/pubmed PY - 2020/7/2/medline KW - antidepressant KW - atypical antipsychotic KW - bipolar depression KW - bipolar disorder KW - pharmacotherapy SP - 1459 EP - 1472 JF - Neuropsychiatric disease and treatment JO - Neuropsychiatr Dis Treat VL - 16 N2 - Depression accounts for the predominant burden associated with bipolar disorder. The identification and management of bipolar depression are challenging, since bipolar depression differs from unipolar depression, responding poorly to traditional antidepressants, which may also induce a switch to hypomania/mania, mixed states and/or cause rapid cycling. Current treatment options for bipolar depression are limited and guidelines vary greatly in their recommendations, reflecting gaps and inconsistencies in the current evidence base. Moreover, some treatment options, such as quetiapine and olanzapine-fluoxetine, although clearly efficacious, may be associated with adverse cardiometabolic side effects, which can be detrimental to the long-term physical health and well-being of patients, increasing the likelihood of treatment non-adherence and relapse. Evidence for some more recent therapeutic options, including lurasidone and cariprazine, suggests that patients' symptoms can be effectively managed without compromising their physical health. In addition, novel agents targeting alternative neurotransmitter pathways and inflammatory processes (such as ketamine and N-acetyl cysteine) are emerging as promising potential options for the treatment of bipolar depression in the future. SN - 1176-6328 UR - https://www.unboundmedicine.com/medline/citation/32606699/Pharmacological_Treatment_of_Bipolar_Depression:_What_are_the_Current_and_Emerging_Options L2 - https://dx.doi.org/10.2147/NDT.S245166 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.